Moderna (MRNA) stock climbed Monday after European regulators granted its Merck (MRK)-partnered personalized cancer vaccine a key designation.
Under the prime scheme designation, the European Medicines Agency gives early feedback on test results to speed up the development and evaluation of medicines that may significantly improve patients' lives. In this case, Moderna and Merck are testing their cancer vaccine in combination with Merck's Keytruda in patients who've had their melanoma surgically removed.
"There is a high unmet need for therapies in melanoma, as it can be a life-threatening condition where available therapies may not be sufficiently effective in a significant proportion of patients," Moderna's president Stephen Hoge said in a written statement.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.